Ohad Hammer

Micromet: More Reasons for Optimism

I am not aware of a SGEN drug for ALL.
They have drugs for all the other acronyms, NHL, AML,MM,HL and ALCL from what I know ;)

SGEN is developing an anti-CD19 antibody drug conjugate but it is still in pre clinical stages, so I don't know which patient population they'll target.

ohad

Micromet: More Reasons for Optimism

I think most of the negative sentiment can be attributed to the break up from Medimmune. I hope that next month MITI will prove that MEDI's decision had nothing to do with the data.
With respect to the discrepancy between fundamentals and market reaction, we'll have to wait and see. I personally believe that we'll see whether the market was right about MITI very soon.

ohad

Micromet: More Reasons for Optimism

Hi Joe

Hopefully you are right regarding the ALL data. One thing is for sure, this company is getting a lot of attention.

Ohad

Bright Prospects for Micromet (Part 2)

You are absolutely right. Should have included that as an option, but I don't think that it's a preferred option for the company.

ohad

'When There's Blood in the Streets', Buy Biotech Stocks

beta delta
I am familiar with the company, but not intimately enough for having an opinion. The idea behind TNFerade is very exciting and has broad applications and the data seems pretty good in pancreatic and H&N cancers. Neverthless, I would be very hesitant in investing in the company before the update in pancreatic cancer, where nothing seems to work.

ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Thanks, KevinMBK.
I don't follow CYPB closely, but I think there is a lot of skepticism towards upcoming phase III results for milnacipran . Their cash position is enviable, no doubt.

Ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Thanks, jturano7423.

I don't think it has a lot to do with guts, but basic common sense ( which seems to be a scarce commodity these days). History shows that people tend to exaggerate to both ways, and what we're witnessing, including today's selloff is merely a result of irrational behavior. Yes, things don't look good at the moment but in my opinion, now is the time to build positions selectively in segments and companies who can weather the storm. I think good biotech companies represent such a tremendous opportunity because their products and technology will always be in demand. Even companies who won't have a commercially available drug in the near future will be able to license drugs and technology to the pharmaceutical giants, who have deep pockets and are starved for new drugs. Remember: There is always a good market for good drugs.
I personally feel much more comfortable buying today, when all the fund managers and investors are dumping everything they have. They were the ones that accumulated all these stocks in the past year or two.

Ohad

'When There's Blood in the Streets', Buy Biotech Stocks

Sorry petpesie, I am not familiar with BioMS. I am sure there are plenty of biotech companies that are suffering as a result of this panic. From what you describe, it is in good position because it has Lilly paying for clinical development, and it doesn't seem that it would stop doing just because there's a recession.

Micromet: Another Seal of Approval

Thanks User 250248!

Thirstycamel, I certainly see your point. Anything can happen with a company like MITI, but anything also includes negative events. A high profile collaboration can certainly lead to another jump in the price of the stock, but if I had to guess, they'll do a secondary very soon. They would be crazy not to...

Ohad

Micromet: Another Seal of Approval

thanks thirstycamel


I suggested taking money off the table because the recent climb wasn't based on anything new, fundamentally and partially because I speculate they’ll do a secondary soon, given the high stock price. I don’t believe in trading biotechs, but in this case, I did sell some MITI on Wednesday, so far an unwise move that cost me money, looking at the current pps…
I think that in many cases, investors ignore timing issues in drug development and although I expect good things from MITI down the road, the next data will be published only in the ASH annual meeting.
You mentioned the SGN-40 deal so there is one final point I want to make. SGEN got such a lucrative deal because it stroke it after the proof of concept clinical trial whereas MITI has already partnered MT103. Had MITI waited till now, they could have gotten a very nice deal.
Ohad

Immunogen and Seattle Genetics: Verging on an Inflection Point

Thanks,

Hopefully next week...

Immunogen and Seattle Genetics: Verging on an Inflection Point

Although IMGN and SGEN are not the only players in the ADC arena, they are the most focused and committed ones. Others such as WYE,IMMU and MEDX are active in the field but none chose to put the pedal to the metal like IMGN and SGEN did.

I don't know a lot about CMC-544's clinical development, as it seems that Wyeth is almost intentionally hiding it. Can you please post links for clinical data?
Ironically, SGEN's naked antibody seems to perform better than both AVE9633 and Mylotarg, so patients will have a drug that is both safe and efficacious. For more on that you can go to my previous SGEN article.

With respect to IMGN's technology, it seems to do the job in the case of T-DM1, which is more impressive than any ADC I am familiar with. Genentech is certainly sold on the technology but what do they know…